Radiotekhnika
Publishing house Radiotekhnika

"Publishing house Radiotekhnika":
scientific and technical literature.
Books and journals of publishing houses: IPRZHR, RS-PRESS, SCIENCE-PRESS


Тел.: +7 (495) 625-9241

 

Biochemical markers in neuroendocrine tumors

Keywords:

N.V. Lyubimova – Dr. Sc.(Biol), Liading Research Scientist, Laboratory of Clinical Biochemistry, N.N. Blokhin Russian Cancer Research Center Ministry of Health of Russian Federation (Moscow)
E-mail: biochimia@mtu-net.ru
T.K. Churikova – Laboratory of Clinical Biochemistry, N.N. Blokhin Russian Cancer Research Center Ministry of Health of Russian Federation (Moscow)
Yu.S. Timofeev – Laboratory of Clinical Biochemistry, N.N. Blokhin Russian Cancer Research Center Ministry of Health of Russian Federation (Moscow)
E-mail: biochimia@mtu-net.ru
M.G. Toms – Ph.D. (Biol.), Senior Research Scientist, Laboratory of Clinical Biochemistry, N.N. Blokhin Russian Cancer Research Center Ministry of Health of Russian Federation (Moscow)
E-mail: biochimia@mtu-net.ru
T.Yu. Kharitidy – Ph.D. (Biol.), Senior Research Scientist, Laboratory of Clinical Biochemistry, N.N. Blokhin Russian Cancer Research Center Ministry of Health of Russian Federation (Moscow)
E-mail: biochimia@mtu-net.ru


The comparative study of chromogranin A (CgA) and serotonine levels in serum as well as 5-HIAA urine excretion were per-formed in 220 patients with neuroendocrine tumors (NETs) and 60 healthy individuals using enzyme immunoassay «Chromogranin A NEOLISA» (Eurodiagnostica), «Serotonin ELISA» и «5-HIAA ELISA»  (IBL International GMBH). All marker levels were significantly higher in patients with NETs compare to healthy subjects (р<0,001). CgA secretion were highly va-riable with the highest value in the group of patients with lung NETs (51587 ng/ml). CgA maximal medians were detected in patients with small intestinal (389 ng/ml), and pancreatic (301 ng/ml) NETs. There was interrelation between CgA, se-rotonin and 5-HIAA levels and extension or activity of NETs. The medians were significantly higher in patients with hepatic metastases and carcinoid syndrome compare to patients without these clinical complications. The diagnostic significance of CgA, serotonin and 5-HIAA was evaluated according to the cutoff values (108 ng/ml, 320 ng/ml, 60 mmol/day, respectively). Diagnostic sensitivity of CgA in whole group of patients was 68,6% (specificity 96,4%). Serotonin and 5-HIAA shows comparable diagnostic sensitivity only in patients with carcinoid syndrome (72,5% and 60,3%). Our study demonstrated high efficiency of CgA as general biochemical marker of NET’s, which determination improves accuracy of diagnostics and evaluation of tumor spreading. Serotonin and 5-HIAA are sensitive biochemical markers of carcinoid syndrome associated with NETs.

References:
  1. Modlin I.M., Latich I., Zikusoka M., Kidd M., Eick G., Chan A.K. Gastrointestinal carcinoids: the evolution of diagnostic strategies // J. Clin. Gastroenterol. 2006. V. 40. № 7. P. 572–582.
  2. Vinik A.I., Silva M.P., Woltering E.A., Go V.L., Warner R., Caplin M. Biochemical testing for neu-roendocrine tumors // Pancreas. 2009. V. 38. № 8. P. 876–889.
  3. Nikou G.C., Marinou K., Thomakos P., Papageorgiou D., Sanzanidis V., Nikolaou P., Kosmidis C., Moulakakis A., Mallas E. Chromogranin A levels in diagnosis, treatment and follow-up of 42 patients with non-functioning pancreatic endocrine tumours // Pancreatology. 2008. V. 8. № 45. P. 510–519.
  4. O'Toole D., Grossman A., Gross D., DelleFave G., Barkmanova J., O'Connor J., Pape U.F., Plöckinger U. Mallorca Consensus Conference participants; European Neuroendocrine Tumor Society. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: biochemical markers. Neuroendocrinology. 2009. V. 90. № 2. P. 194–202.
  5. Modlin I.M., Gustafsson B.I., Moss S.F., Pavel M., Tsolakis A.V., Kidd M. Chromogranin A - biological function and clinical utility in neuroendocrine tumor disease // Ann. Surg. Oncol. 2010. V. 17. №. 9. P. 2427–2443.
  6. Ardill J.E. Circulating markers for endocrine tumours of the gastroenteropancreatic tract // Ann. Clin. Biochem. 2008. V. 45. №. 6. P. 539–559.
  7. Ljubimova N.V., Churikova T.K., Kushlinskij N.E. Hromogranin A–biohimicheskij marker nejrojendokrinnyh opuholej // Bjulleten' jeksperimental'noj biologii i mediciny. 2015. T. 160. № 1. S. 657–660.
  8. Lesurtel M., Soll C., Graf R., Clavien P.A. Role of serotonin in the hepato-gastrointestinal tract: an old molecule for new perspectives // Cell Mol. Life Sci. 2008. V. 65. № 6. P. 940–952.
  9. Louthan O. Chromogranin A in physiology and oncology // Folia Biol. 2011. V. 57. № 5. P. 173–181.
  10. Zuetenhorst J.M., Korse C.M., Bonfrer J.M., Peter E., Lamers C.B., Taal B.G. Daily cyclic changes in the urinary excretion of 5-hydroxyindoleacetic acid in patients with carcinoid tumors // Clin. Chem. 2004. V. 50. №. 9. P. 1634–1639.
  11. Braga F., Ferraro S., Mozzi R., Dolci A., Panteghini M. Biological variation of neuroendocrine tumor markers chromogranin A and neuron-specific enolase // Clin. Biochem. 2013. V. 46. № 12. P. 148–151.
  12. Oberg K. Circulating biomarkers in gastroenteropancreatic neuroendocrine tumours // Endocr. Relat. Cancer. 2011. V. 18. № 1. P. 17–25.
  13. Ljubimova N.V., Kushlinskij N.E. Biohimicheskie markery nejrojendokrinnyh opuholej // Voprosy biologicheskoj, medicinskoj i farmacevticheskoj himii. 2014. №1. S. 1–11.
  14. Singh S., Law C. Chromogranin A: a sensitive biomarker for the detection and post-treatment monitoring of gastroenteropancreatic neuroendocrine tumors // Expert Rev. Gastroenterol. Hepatol. 2012. V. 6. № 3. P. 313–334.

© Издательство «РАДИОТЕХНИКА», 2004-2017            Тел.: (495) 625-9241                   Designed by [SWAP]Studio